rethinkPeptides Search
Menu
Study breakdown

A Peptide from Kefir Lowered Blood Pressure and Protected Blood Vessels in Hypertensive Mice

evidence
The takeaway

Kef-1, an ACE-inhibiting peptide derived from kefir fermentation, reduced blood pressure, oxidative stress, and vascular damage in a mouse model of hypertension.

ACE inhibitor from kefir

Kef-1 inhibits the same enzyme targeted by prescription blood pressure drugs, and showed anti-hypertensive effects in a mouse model

What the researchers found

Kef-1 peptide reduced ROS production and improved vascular structure in 2K1C mice.

Why it matters

Understanding how Kef-1 works could lead to new treatments for hypertension and related cardiovascular diseases. This research highlights the potential of natural compounds in managing health conditions.

How the study worked

The study used an angiotensin II-dependent hypertension model in 2K1C mice to evaluate the effects of Kef-1.

What this study cannot tell us

The study was conducted in mice, and results may not directly translate to humans. Further research is needed to confirm efficacy in human populations.

How to read the evidence

This is a preclinical study using a well-established mouse model of hypertension (2K1C) with both in vivo and in vitro components. The 'Preliminary' grade reflects that while the animal results are promising, no human data exists for Kef-1 specifically.

When this study was published

Published in 2022 in Food & Function, this is a recent study in the growing field of food-derived bioactive peptides. The findings are current and reflect modern analytical approaches to nutraceutical research.

The bigger picture

Food-derived bioactive peptides — from kefir, milk, fish, and other sources — are an increasingly active area of research in cardiovascular health. ACE-inhibitory peptides produced during fermentation may partly explain why fermented dairy consumption is associated with lower blood pressure in observational studies. Kef-1 adds to a growing library of food peptides that could become nutraceutical interventions for hypertension.

Questions still open

  • Does drinking kefir provide enough Kef-1 to produce meaningful blood pressure effects in humans?
  • How does Kef-1's ACE inhibitory potency compare to prescription ACE inhibitors like lisinopril?
  • Could Kef-1 be developed as a nutraceutical supplement for mild hypertension?

Common questions

What is Kef-1 and how does it relate to drinking kefir?
Kef-1 is a specific peptide produced when kefir bacteria and yeast ferment milk proteins. It acts as a natural ACE inhibitor — blocking the same enzyme that prescription blood pressure drugs target. While drinking kefir exposes you to many bioactive peptides including Kef-1, it's unclear how much active Kef-1 survives digestion and reaches the bloodstream in meaningful amounts.
Could this peptide replace blood pressure medication?
Not based on current evidence. This is a mouse study showing promising results, but no human trials have been conducted with isolated Kef-1. Prescription ACE inhibitors have decades of clinical data supporting their use. However, food-derived ACE-inhibiting peptides like Kef-1 could potentially serve as complementary approaches to blood pressure management or as preventive nutraceuticals.

Read the original research

Use of kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice.

Food & function, 13(4), 1965-1974

Citation

Aires, Rafaela; Gobbi Amorim, Fernanda; Côco, Larissa Zambom; da Conceição, Amanda Pompermayer; Zanardo, Tadeu Ériton Caliman; Taufner, Gabriel Henrique; Nogueira, Breno Valentim; Vasquez, Elisardo Corral; Melo Costa Pereira, Thiago; Campagnaro, Bianca Prandi; Dos Santos Meyrelles, Silvana. (2022). Use of kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice.. Food & function, 13(4), 1965-1974. https://doi.org/10.1039/d1fo01798e